Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05159245 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

Study acronym: FINPROVE
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 4 to 5
    • Interventions: Abemaciclib (Drug), Alectinib (Drug), Apalutamide (Drug), Atezolizumab (Drug), Cobimetinib (Drug), Dabrafenib (Drug), Dabrafenib+Trametinib… to Abemaciclib (Drug), Alectinib (Drug), Apalutamide (Drug), Atezolizumab (Drug), Cobimetinib (Drug), Dabrafenib (Drug), Dabrafenib+Trametinib…
    • Eligibility criteria expanded, about 44 words
    v8
  2. Eligibility criteria shortened, about 10 words
    • Site contacts updated at 1 of 4 sites
    • Study description expanded, about 2 words
    v7
  3. Study sites: 3 to 4
    • Interventions: Abemaciclib (Drug), Alectinib (Drug), Apalutamide (Drug), Atezolizumab (Drug), Cobimetinib (Drug), Dabrafenib (Drug), Dabrafenib+Trametinib… to Abemaciclib (Drug), Alectinib (Drug), Apalutamide (Drug), Atezolizumab (Drug), Cobimetinib (Drug), Dabrafenib (Drug), Dabrafenib+Trametinib…
    • Study arms: 14 to 15
    v6
  4. Interventions: Abemaciclib (Drug), Alectinib (Drug), Apalutamide (Drug), Atezolizumab (Drug), Cobimetinib (Drug), Entrectinib (Drug), Regorafenib (Drug)… to Abemaciclib (Drug), Alectinib (Drug), Apalutamide (Drug), Atezolizumab (Drug), Cobimetinib (Drug), Dabrafenib (Drug), Dabrafenib+Trametinib…
    • Study description expanded, about 10 words
    • Study arms: 11 to 14
    v5
  5. Study sites: 1 to 3v4
Show 2 earlier versionsHide 2 earlier versions
  1. Interventions: Alectinib (Drug), Atezolizumab (Drug), Cobimetinib (Drug), Entrectinib (Drug), Regorafenib (Drug), Trastuzumab+Pertuzumab (Drug)… to Abemaciclib (Drug), Alectinib (Drug), Apalutamide (Drug), Atezolizumab (Drug), Cobimetinib (Drug), Entrectinib (Drug), Regorafenib (Drug)…
    • Study arms: 8 to 11
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test.
Trial Details
NCT Number NCT05159245
Lead Sponsor Helsinki University Central Hospital
Conditions
(from sponsor)		 Advanced Cancer, Solid Tumor, Haematological Malignancy
Related terms Hematologic Neoplasms
Enrollment 250 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov